Disclosed herein are therapeutic compounds capable of targeting abroad range of tumor cells. The present disclosure is further directed to compositions comprising the therapeutic compounds, methods of manufacturing the therapeutic compounds, and methods of treating cancer comprising administering the therapeutic compounds.

Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination. Also provided herein are lipid nanoparticle compositions comprising said lipids.

Certain embodiments describe antiviral compounds and related methods of using such compounds.

Certain embodiments describe antiviral compounds and related methods of using such compounds.

The novel bisphosphonic acid ester derivatives represented by the following formula (1):

Y—Cy—(NH).sub.m—(CH.sub.2).sub.n—C(X)(PO(OR.sup.1)(OR.sup.2)).sub.2   (1)

wherein each symbol is as defined in the DESCRIPTION, which has an amino group substituted by a heterocyclic group or a heterocyclic group containing a nitrogen atom, and the acid moiety is esterified with a POM group, an n-butanoyloxymethyl (BuOM) group and the like, exhibit a superior direct or indirect cytotoxicity effect on tumor cells and virus infected cells.

The novel bisphosphonic acid ester derivatives represented by the following formula (1):

Y—Cy—(NH).sub.m—(CH.sub.2).sub.n—C(X)(PO(OR.sup.1)(OR.sup.2)).sub.2   (1)

wherein each symbol is as defined in the DESCRIPTION, which has an amino group substituted by a heterocyclic group or a heterocyclic group containing a nitrogen atom, and the acid moiety is esterified with a POM group, an n-butanoyloxymethyl (BuOM) group and the like, exhibit a superior direct or indirect cytotoxicity effect on tumor cells and virus infected cells.

The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula I: ##STR00001##
wherein the variables are as defined herein.

The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula I: ##STR00001##
wherein the variables are as defined herein.

Provided is a compound of Chemical Formula 1:
HAr-L1-L2-Ar1  Chemical Formula 1 wherein: HAr is a group of the following Chemical Formula A-1 or A-2; L1 and L2 are the same as or different from each other, and each independently is a direct bond, a substituted or unsubstituted monocyclic or polycyclic arylene group, or a substituted or unsubstituted monocyclic or polycyclic heteroarylene group; and Ar1 is a substituted or unsubstituted monocyclic or polycyclic aryl group, or a substituted or unsubstituted monocyclic or polycyclic heteroaryl group; ##STR00001## wherein: R1 to R3 are the same as or different from each other, and each independently is a substituted or unsubstituted linear or branched alkyl group; and ##STR00002##
is a site bonding to L1 of Chemical Formula 1,
and an organic light emitting device comprising the same.

Provided is a compound of Chemical Formula 1:
HAr-L1-L2-Ar1  Chemical Formula 1 wherein: HAr is a group of the following Chemical Formula A-1 or A-2; L1 and L2 are the same as or different from each other, and each independently is a direct bond, a substituted or unsubstituted monocyclic or polycyclic arylene group, or a substituted or unsubstituted monocyclic or polycyclic heteroarylene group; and Ar1 is a substituted or unsubstituted monocyclic or polycyclic aryl group, or a substituted or unsubstituted monocyclic or polycyclic heteroaryl group; ##STR00001## wherein: R1 to R3 are the same as or different from each other, and each independently is a substituted or unsubstituted linear or branched alkyl group; and ##STR00002##
is a site bonding to L1 of Chemical Formula 1,
and an organic light emitting device comprising the same.